NKX2-2

Across TCGA pan-cancer cohorts, NKX2-2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of NKX2-2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NKX2-2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NKX2-2 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

HNSC, COAD, and BRCA are the cancer types where NKX2-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NKX2-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+0.761	.001	8	view →
COAD	Male	II,III,IV	−0.574	<.001	8	view →
BRCA	Female	II,III,IV	+0.419	<.001	6	view →
THCA	Male	All	−0.035	.007	4	view →
LIHC	All	All	+0.032	.010	3	view →
PRAD	All	All	+0.465	.006	2	view →
UCEC	All	IV	+0.075	.037	2	view →
STAD	Male	IV	−0.605	.040	1	view →
KIRC	All	All	+0.090	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

NKX2-2–HNSC

Open the HNSC breakdown →